(Q64183747)

English

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico (English)

0 references

0 references

0 references

dengue hemorrhagic fever

0 references

start time

16 November 2016

0 references

end time

31 October 2018

0 references

number of participants

480

0 references

clinical trial phase

phase III clinical trial

0 references

minimum age

9 year

0 references

maximum age

14 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02979535

0 references

(Q64183747)

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)